Reference: Généreux, et al, for the PARTNER Trial Investigators. JACC 2012; 60 (12):1043-62 Original title: Vascular complications after Transcatheter Aortic Valve Replacement: Insights From the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial The purpose of the study was to investigate the incidence, predictors and vascular complications impact after catheter aortic valve implantation (TAVI) in the PARTNER…
TAVI, more risky in patients with peripheral vascular disease
Reference: Sinning et al. AHJ Am Heart J 2012;164:102-110 Percutaneous aortic valve replacement (TAVI) is a novel technique for the treatment of severe aortic stenosis (SAS) that has been built with great enthusiasm in clinical practice, particularly in patients with excessive surgical risk. In these patients, a high obstructive peripheral vascular disease stands, a fact…
Global Risk Score for stratification of patients with multivessel coronary artery disease: A wider look
Reference: Serruys et al J Am Coll Cardiol Intv 2012;5:606–17 SYNTAX Analysis study demonstrates the utility of a new risk score for patients stratification with left main coronary artery or multivessel disease. Numerous studies have demonstrated the value of SYNTAX score to stratify risk of angioplasty and decision-making (angioplasty versus surgery) in patients with multivessel…
The impact of permanent pacemaker implantation in patients undergoing percutaneous aortic valve replacement.
Reference: Buellesfeld y colaboradores (JACC in press). Percutaneous aortic valve replacement (AVR) is an innovative technique for the treatment of severe aortic stenosis (SAS); this technique has been incorporated with great enthusiasm in clinical practice, particularly for patients with excessive surgical risks. Due to the proximity of the aortic valve, AV node and His bundle, there…
Renal failure in acute myocardial infarction
Reference: Fox y colaboradores. Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry. Circulation 2012 (in press). The presence of chronic renal failure is common in patients referred for angioplasty. Its presence is associated with increased mortality and bleeding. However, the prevalence is unknown as…
Hyperglycemia on admission, an excess risk for infarction
Reference: Planer et al. International Journal of Cardiology 2012 (in press) Prognosis of patients enrolled in acute myocardial infarction with ST segment elevation (STEMI) has improved markedly, particularly as a result of reperfusion therapy. Despite these improvements, patients with diabetes mellitus (DM) are a high risk group in the short and long term compared with…
Unstable Angina
Reference: Jneid y colaboradores. JACC 2012 (inpress).
Percutaneous closure of the appendage: results, evidence, team training.
Our editors talked with Dr. Aníbal Damonte Percutaneous closure of left atrial appendage is now a practice that is becoming more topical with a view to results and perspectives. In this regard, we interviewed Dr. Aníbal Damonte, interventional cardiologist at the Cardiovascular Institute of Rosario (Rosario, Argentina). WEB SOLACI: May I first ask you to…
In patients with stroke history, Ticagrelor is superior to Clopidogrel
James SK, Storey RF, Khurmi N, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation 2012. A sub-analysis of the PLATO study demonstrated similar superiority and the safety of ticagrelor in all patients, regardless of any previous history of stroke. Ticagrelor versus clopidogrel:…
Six Months Sufficient for Dual Antiplatelet Therapy
Reference: Kandzari DE, Barrer CS, Leon MB, et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 2011; 4: 1119-28.2011; 4: 1119-28. Patients treated with zotarolimus-eluting stents (ZES) suffer no excess late ischemic events if they take dual antiplatelet therapy for 6 months instead of 12 months or longer,…